The impact of patients' pre‐treatment expectations on immunosuppressive treatment outcomes in myasthenia gravis: A pilot correlational study
Authors:
- Elisa FrisaldiEFElisa Frisaldi
- Diletta BarbianiDBDiletta Barbiani
- Eleonora Maria CameroneECEleonora Maria Camerone
- Alessandro PiedimonteAPAlessandro Piedimonte
- Jan VollertJVJan Vollert
- Maurizio ZibettiMZMaurizio Zibetti
- Leonardo LopianoLLLeonardo Lopiano
- Aziz ShaibaniASAziz Shaibani
- Fabrizio BenedettiFBFabrizio Benedetti
- 28 June 2024
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 70 (3) , 413-419
Abstract
Introduction/Aims: The impact of treatment expectations on active treatment outcomes has not been specifically investigated in neuromuscular disorders. We thus explored in myasthenia gravis (MG) the contribution of patients' pre‐treatment expectations combined with an immunosuppressant drug on treatment outcomes.Methods: This pilot correlational study involved 17 patients with generalized MG, scheduled to start immunosuppressant azathioprine. At baseline, a healthcare professional administered: (i) the Stanford Expectations of Treatment Scale; (ii) a structured checklist paper form asking patients which side‐effects they expected to develop after starting azathioprine, coupled with a standardized framing of statements. Quantitative Myasthenia Gravis (QMG) score and daily dose of concomitant drugs were assessed by neurologists as clinical outcomes. Clinical outcomes and side‐effects were re‐assessed at 3 and 6 months, and clinical outcomes were monitored at 18 months.Results: Clinically significant improvement in the QMG scores was achieved at 3 or 6 months. The level of state anxiety appeared to act as moderator of pre‐treatment negative expectations (strong, positive, indicative correlation, rs = .733, p = .001). The latter were, in turn, associated with the fulfillment of side‐effects that patients expected to develop with the new treatment (moderate, positive, indicative correlation, rs = .699, p = .002). No significant correlation emerged between positive and negative expectations.Discussion: Our findings show a very quick clinical response and also suggest that patients' expectations and anxiety contributed to treatment outcomes, highlighting the importance of promoting safety messages and education strategies around newly introduced treatments. Future goals include evaluating a larger cohort that includes a matched control group.Keywords
This publication has 18 references indexed in Scilit:
- The humanistic burden of myasthenia gravis: A systematic literature reviewJournal of the Neurological Sciences, 2022
- Placebo 2.0: the impact of expectations on analgesic treatment outcomePain, 2020
- Fear in the context of pain: Lessons learned from 100 years of fear conditioning researchBehaviour Research and Therapy, 2020
- Placebo and Nocebo EffectsNew England Journal of Medicine, 2020
- The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A meta‐analysisMuscle & Nerve, 2019
- Treatment of Myasthenia GravisNeurologic Clinics, 2018
- Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disordersMuscle & Nerve, 2017
- Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trialMuscle & Nerve, 2013
- Azathioprine in the treatment of myasthenia gravisAnnals of Neurology, 1984
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961